Shionogi & Co Ltd - Company Profile
Powered by 
All the data and insights you need on Shionogi & Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Shionogi & Co Ltd Strategy Report
- Understand Shionogi & Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Shionogi & Co Ltd (Shionogi) focuses on the research, development, manufacturing, and marketing of pharmaceutical products, diagnostic reagents, and medical devices. It develops innovative products and services in collaboration with its partners. The company offers prescription drugs, over-the-counter (OTC) drugs, and diagnostic products for the therapeutic areas including metabolic disorders, pain/central nervous system (CNS), infectious diseases and cancer. It offers contract development and manufacturing facilities including all stages from drug development to commercial manufacturing. The company operates a network of subsidiaries, branches, sales offices manufacturing plants, and research laboratories across Japan, China, Taiwan; North America and Europe. Shionogi is headquartered in Osaka, Japan.
Headquarters
Japan
Address
3-1-8, Dosho-Machi, Chuo-Ku, Osaka-Shi, 541-0045
Website
www.shionogi.com
Telephone
81 6 62022161
No of Employees
5,680
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4507 (TYO)
Revenue (2022)
$3.2B
27.3%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
62%
(2022 vs 2021)
Market Cap*
$13.8B
Net Profit Margin (2022)
XYZ
27.2%
(2022 vs 2021)
* As of and is in US$
Shionogi & Co Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Prescription Drugs: | Contract Manufacturing Services | Rizmoic |
| Crestor | Symproic | |
| Cymbalta | Simploic | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In March, the company announced a collabration with Nagasaki University to commence drug discovery research in malaria. |
| 2024 | Contracts/Agreements | In February, the company and FRONTEO entered into a strategic business partnership agreement for the dementia-related AI program and depression-related AI program. |
| 2023 | Contracts/Agreements | In December, Ping-An Shionogi Hong Kong signed an agreement with Juniper Therapeutix for a license for the rights to Ensitrelvir Fumaric Acid for Singapore. |
Competitor Comparison
| Key Parameters | Shionogi & Co Ltd | Takeda Pharmaceutical Co Ltd | Daiichi Sankyo Co Ltd | Chugai Pharmaceutical Co Ltd | Santen Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Osaka-Shi | Chuo-Ku | Chuo-Ku | Chuo-Ku | Osaka-Shi |
| State/Province | Osaka | Tokyo | Tokyo | Tokyo | Osaka |
| No. of Employees | 5,680 | 49,095 | 17,435 | 7,771 | 4,144 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Takuko Sawada | Director; Vice Chairman | Executive Board | 2022 | - |
| Isao Teshirogi, Ph.D. | Chief Executive Officer; Director; President | Executive Board | 2008 | - |
| Tatsumori Yoshida | Chairman - Ping An Shionogi Company Ltd and Ping An Shionogi (Hong Kong) Company Ltd; Corporate Officer; Chief Executive Officer - Ping An Shionogi Company Ltd and Ping An Shionogi (Hong Kong) Company Ltd | Executive Board | 2018 | - |
| Koji Hanasaki, Ph.D. | Senior Executive Officer; Senior Vice President - Global Business Division; Corporate Officer | Senior Management | 2018 | - |
| Kazuhiro Hatanaka | Senior Executive Officer; Senior Vice President - Administration Division | Senior Management | 2018 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward